<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Goeders, Nathalie</style></author><author><style face="normal" font="default" size="100%">Vanneste, Kevin</style></author><author><style face="normal" font="default" size="100%">Roosens, Nancy H.C.</style></author><author><style face="normal" font="default" size="100%">Bogaerts, Bert</style></author><author><style face="normal" font="default" size="100%">Wesley Mattheus</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">4CMenB vaccine coverage of invasive serogroup B meningococci collected in Belgium between 2016 and 2022</style></title><secondary-title><style face="normal" font="default" size="100%">Human Vaccines &amp; Immunotherapeutics</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Immunization</style></keyword><keyword><style  face="normal" font="default" size="100%">meningococcal disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Neisseria meningitides</style></keyword><keyword><style  face="normal" font="default" size="100%">Serogroup B</style></keyword><keyword><style  face="normal" font="default" size="100%">vaccine coverage</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jul-12-2027</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">21</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;&lt;em&gt;Neisseria meningitidis&lt;/em&gt; infections can cause life-threatening meningitis and septicemia. In Europe, serogroup B (MenB) is the leading cause of invasive meningococcal disease (IMD), particularly in young children. Genomic surveillance of circulating MenB strains through whole genome sequencing (WGS) provides a powerful tool to assess the potential impact of vaccination strategies, including the 4CMenB vaccine, which is available for infants from 2 months of age. Here, we present a retrospective WGS based analysis of clinical MenB IMD cases (n = 311) recovered in Belgium from 2016 to 2022 by the Belgian National Reference Center. High-quality WGS data were obtained for 281 of these strains, demonstrating high genetic diversity of the antigen targets included in the 4-component meningococcal serogroup B vaccine 4CMenB (fHbp, PorA, NHBA and NadA) and at the 4CMenB Antigen Sequence Types (BAST) level. Novel antigen combinations, not yet assigned a BAST ID, were detected in 23.5% of isolates. Vaccine coverage was predicted using the Genetic Meningococcal Antigen Typing System (gMATS) and the Meningococcal Deduced Vaccine Antigen Reactivity (MenDeVAR) index. Of the 281 strains, 79.5% (lower limit–upper limit: 68.0–91.5%) were predicted to be covered by the vaccine by gMATS, and 80.7% (lower limit–upper limit: 66.5–95.4%) by MenDeVAR. No evidence of variation in vaccine coverage was found throughout the study period nor between different age groups, demonstrating the broad applicability of 4CMenB. This study highlights the benefits of a pathogen surveillance program and the need for experimental characterization of continuously evolving antigenic subvariants of &lt;em&gt;Neisseria meningitidis&lt;/em&gt;.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue></record></records></xml>